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 Disclosure of Information to Potential Subjects on
 Research Recruitment Web Sites
 BY ROBERT KLITZMAN, ILENE ALBALA, JOSEPH SIRAGUSA, JIGNASHA PATEL, AND PAUL S. APPELBAUM
 Recruitment practices in clini-
 cal research may be changing
 rapidly as use of the Internet
 grows. Last year, 73% of
 Americans were reported to be
 using the Internet.' Yet despite the
 developing influence of the Internet
 as a tool for reaching potential sub-
 jects, few systematic studies have
 been conducted that explore how
 individuals are recruited via the
 Internet for research studies or
 what type of information clinical
 trial Web sites provide to prospec-
 tive research participants.
 In zooz, the Department of
 Health and Human Services'
 (DHHS) Office of Inspector General
 (OIG) examined zz Web sites-fed-
 eral sites, third-party sites, location-
 specific sites, sponsor-specific sites,
 and others-that listed a total of 11o
 clinical trials. Of these zz sites, zi
 explained the importance of
 informed consent, and 16 described
 the role of Institutional Review
 Boards (IRBs). However, of the 110o
 trials listed, only 29 mentioned
 potential research benefits, while
 none mentioned potential risks.
 Some Web sites provided misleading
 information (e.g., referring to "new
 drug treatments" rather than "exper-
 imental" or "unproven drugs"). Of
 note, this zooz report did not
 describe how the particular Web
 sites within each category were cho-
 sen.
 Based on its review, the OIG rec-
 ommended that the Food and Drug
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 Administration (FDA) and the Office
 for Human Research Protections
 (OHRP) provide guidance to IRBs
 concerning clinical trial Web sites;
 that risk and benefit information be
 balanced and subject to IRB review;
 that use of voluntary standards by
 Web sites be facilitated; and that
 Web sites be reviewed periodically
 by independent bodies. Subsequently,
 in September 2005, the OHRP
 issued a report, "Guidance on
 Institutional Review Board Review
 of Clinical Trial Websites," that stat-
 ed:
 When information posted on a clin-
 ical trial website goes beyond direc-
 tory listings with basic descriptive
 information, such information is
 considered part of the informed
 consent process and thus requires
 IRB review and approval. Basic
 descriptive information includes:
 study title, purpose of the study,
 protocol summary, basic eligibility
 criteria, study site location(s), and
 how to contact the study site for
 further information. Information
 exceeding such basic listing infor-
 mation includes descriptions of clin-
 ical trial risks and potential bene-
 fits.... IRBs should pay particular
 attention to risk and potential bene-
 fit information to ensure it is pre-
 sented in a balanced and fair man-
 ner. IRBs reviewing clinical trial
 Web sites also should assess the
 types of incentives, if any, being
 offered to prospective subjects.
 Monetary and non-monetary incen-
 tives (e.g., access to services or pro-
 grams) can create undue influence
 on a potential subject's decision
 about participation.2
 Even before the OHRP issued its
 guidance, the FDA had provided
 essentially the same guidance for IRB
 review of clinical trial Web sites. In
 1998, the FDA noted in its docu-
 ment, "Guidance for Institutional
 Review Boards and Clinical
 Investigators," that
 IRB review and approval may
 assure that .., additional informa-
 tion does not promise or imply a
 certainty of cure or other benefit
 beyond what is contained in the
 protocol and the informed consent
 document.3
 The FDA has also pointed out
 that it "considers direct advertising
 for study subjects to be the start of
 the informed consent and subject
 selection process,"4 and the OHRP
 has said that "in some cases, the
 information provided on these [clini-
 cal trial] websites may constitute the
 earliest components of the informed
 consent process."s
 Clearly, this regulatory guidance
 is important, yet the degree to which
 trial sponsors, Principal Investigators
 (PIs), and IRBs follow FDA and
 OHRP guidance has not been exam-
 ined. Web sites may provide the first
 information that a potential research
 subject sees about a study, and anec-
 dotal information suggests that some
 individuals decide to enroll in a
 study before they have even seen the
 informed consent document or par-
 ticipated in the informed consent
 process. From a theoretical perspec-
 tive, Kahneman and Tversky6 have
 described an "anchoring heuristic,"
 whereby initial information provided
 to an individual "anchors" or estab-
 lishes a mental framework that
 shapes views and the ways in which
 information is weighed and may
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 affect subsequent decisions. Research
 has shown that even the order in
 which risks and benefits are present-
 ed can influence perceptions.7
 Studies have explored potentially
 related areas: print and Web site
 advertisements that recruit job appli-
 cants; print ads for recruiting
 research participants; and Web sites
 for clinical services. For example, job
 recruitment ads that enhance the
 physical features of the advertise-
 ment (e.g., white space, size, border,
 and graphics) increase the quantity
 of applicants.8 In online job ads,
 navigational ease may be related to
 positive impressions.9 Print ads are
 often used to recruit research partici-
 pants,'0 but studies have focused on
 their cost-effectiveness" rather than
 their mention of risks, benefits, or
 other key aspects of their content.
 The American Medical Association
 (AMA) has issued guidelines for clin-
 ical Web sites that provide medical
 and health information," but these
 guidelines often are not followed.'3
 Recently, particular controversy
 has arisen regarding the role of
 incentives in recruitment for partici-
 pation in clinical trials, including
 their appropriateness and influence
 on the decision whether to enroll.
 Emanuel has argued that IRBs are
 too concerned about "undue induce-
 ment"4 as opposed to risk and
 informed consent. But controversy
 remains regarding the possibility of
 undue inducement, and ambiguity
 continues about how to define undue
 influence.'s Few empirical studies
 have probed what roles payments or
 other incentives have on potential
 participants' decisions. Payments
 vary widely at institutions that com-
 pensate research subjects,'6 and
 amounts of payment may correlate
 with willingness to participate.'7 But
 how often protocols in fact compen-
 sate participants remains unknown.
 Hence, the presence of information
 about incentives on Web sites may
 be of added interest, as it may help
 inform these discussions.
 In order to learn more about these
 issues, we examined systematically
 how a sample of Web sites that
 recruit participants for research on
 particular diseases present studies to
 potential subjects, exploring the pres-
 ence of information about research
 benefits, risks, procedures, and
 incentives, including monetary incen-
 tives. Such data can elucidate the
 degree to which federal guidance is
 being followed and may have poten-
 tial implications for policy, suggest-
 ing areas that IRBs, policy-makers,
 and regulators may want to consider
 further regarding online recruiting of
 research participants.
 Study Methods
 To obtain a systematic, diverse
 sample of research studies, we
 chose two areas of clinical
 research-diabetes and depression-
 since both disorders are fairly com-
 mon (with United States lifetime
 prevalence nearly 7% for diabetesl8
 and 13 % for depression"9), are much
 investigated, and involve a range of
 types of studies and patient popula-
 tions. We decided to simulate the
 steps that a prospective research par-
 ticipant might take. Specifically, we
 conducted online searches with the
 GoogleTM search engine, entering the
 terms "participate in diabetes
 research study" and "participate in
 depression research study." We
 included Web sites that were actively
 recruiting research subjects. All dia-
 betes sites were included. Of depres-
 sion sites, we included those for
 studies of unipolar depression and
 excluded those for studies of bipolar
 disorder to allow for more uniformi-
 ty, given the many differences
 between these two disorders, and to
 reduce other potentially confounding
 variables (e.g., studies of bipolar dis-
 order often involve treatment of both
 depression and mania). For studies
 that had one common set of proce-
 dures and then additional optional
 procedures, we included only those
 parts of the study in which all sub-
 jects would participate. For each dis-
 ease category, we analyzed the first
 30 Web sites, of which 22 diabetes
 and 21 depression sites met inclusion
 criteria (i.e., provided information
 for recruiting participants to a
 study). Because many Web sites list-
 ed more than one study, each study
 was examined separately.
 Specifically, of the zz and zi Web
 sites for diabetes and depression,
 respectively, 17 (77%) and 18 (86%)
 listed multiple studies, and five
 (23%) and three (14%) listed single
 studies.
 Our search procedures yielded a
 total of 171 diabetes and 184
 depression studies that we then ana-
 lyzed. The goal of this sampling
 strategy was to obtain a sufficient
 number of Web sites in each catego-
 ry to be able to explore similarities,
 differences, and patterns that might
 appear. Each search was performed
 once in June zoo6, with sites
 accessed on the same day (as results
 generated by search engines may
 change over time). All Web site and
 recruiting information was then
 printed and analyzed.
 We examined and coded charac-
 teristics of the information on the
 Web sites, including mention of:
 * whether the study was described
 as a clinical trial;
 * whether a drug was adminis-
 tered or a device was used in the
 study, and if so, if these studies
 appeared to be more than minimal
 risk;
 * any additional research proce-
 dures involving more than minimal
 risk (e.g., assessment procedures
 more invasive than drawing blood,
 such as lumbar puncture and electro-
 convulsive therapy (ECT), but not
 including the use of medications or
 devices, if these were already coded);
 * whether sites mentioned the
 terms "risk(s)" or "side effect(s)";
 * whether the sites referred in any
 other way to risk(s);
 * any incentive (financial or nonfi-
 nancial);
 * whether a financial incentive
 was offered, and, if one was, the spe-
 cific amount that the participant
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 would be paid;
 * whether a nonfinancial incentive
 was offered, and, if so, what it was
 (i.e., free treatment, medication, or
 evaluation);
 * the number of visits involved in
 study participation;
 * the length of the study; and
 * the source of sponsorship (i.e.,
 government, not-for-profit, or for-
 profit).
 Since, as presented below, very few
 studies explicitly mentioned such
 source of sponsorship, we also
 assessed whether the contact person
 listed was at a for-profit or not-for-
 profit institution (revealed through
 affiliation on email or street
 address-e.g., a university vs. a phar-
 maceutical company). Finally, we
 assessed how financial incentives
 were presented in recruiting sites:
 whether mention of financial incen-
 tives used different font size or
 appearance (italics, bold, underline,
 or all capital letters) or other charac-
 ters (exclamation points or asterisks)
 to emphasize this information.
 We divided studies into two
 groups: those that appeared to
 involve more-than-minimal-risk
 intervention or assessment, and those
 that did not. We were guided by the
 assumption that studies in which
 medication is administered are gener-
 ally more-than-minimal risk, due to
 the medication itself as well as possi-
 ble assessment procedures. Studies
 that appeared to involve a more-
 than-minimal-risk intervention or
 assessment included those that
 administered medications or devices
 (e.g., insulin pumps, investigational
 devices, and transcranial magnetic
 stimulation--113 [66%] diabetes
 studies and 140 [76%] depression
 studies) or other active substances
 such as hormones or alcohol (two
 [1%] diabetes studies and two [1%]
 depression studies). They also includ-
 ed those that administered and/or
 mentioned an additional procedure
 other than administration of a med-
 ication or a device that involved
 more than minimal risk (specifically,
 muscle biopsy, gene transfer, intra-
 venous catheter, intravenous infu-
 sion, and lumbar punctures-four
 [z%] diabetes studies and two [1%]
 depression studies). For diabetes, the
 four studies that listed additional,
 more-than-minimal-risk procedures
 also involved administration of a
 drug or device. Studies that did not
 appear to involve a more-than-mini-
 mal-risk procedure included those
 that administered vitamins, massage
 therapy, exposure to light, acupunc-
 ture, etc. We also included in this
 second group studies that involved
 ongoing use of psychoactive drugs
 (30% diabetes and 19% depression),
 since these studies did not appear to
 impose a higher degree of risk than
 the subject would otherwise
 encounter in his or her daily life. In
 all, the more-than-minimal-risk stud-
 ies comprised 67% and 77% of the
 diabetes and depression studies,
 respectively. A research assistant
 coded the information on the sites,
 and decisions and any questions that
 arose were reviewed and resolved by
 the consensus of the team. We con-
 ducted Fisher's Exact Tests to deter-
 mine differences between the two
 diseases on each of these characteris-
 tics and within each disease category
 to identify relationships among Web
 site characteristics.
 Results
 As shown in Table 1 (http://www.
 thehastingscenter.org/pdf/irb_
 2007_novdec klitzman_tables.pdf),
 of the study descriptions for diabetes
 (N = 171) and depression (N = 184),
 most mentioned financial or nonfi-
 nancial incentives (73% diabetes and
 75% depression). Fifty-four percent
 of the diabetes studies and 46% of
 the depression studies mentioned
 financial incentives only; 12 z% of the
 diabetes studies and 20zo% of the
 depression studies listed specific
 amounts. Forty-seven percent of the
 diabetes studies and 6z% of the
 depression studies listed free medica-
 tions or treatment as incentives.
 Only one study stated that no finan-
 cial incentives would be offered.
 Fewer than half of the studies
 examined reported study length
 (43% diabetes and 38% depression).
 Roughly one-third or fewer (34%
 diabetes and 18% depression) listed
 the number of visits required. Few
 studies mentioned a research proce-
 dure besides administration of a
 medication or device that appeared
 to be more-than-minimal risk (z%
 diabetes and 1% depression). None
 of the studies used the terms "risk"
 or "risks." The only use of the term
 "side effect(s)" was in reference to a
 study of "mild brain stimulation," in
 which the Web site stated, "Very
 weak currents are used to stimulate
 the brain. The stimulation is painless
 with no known serious side effects,
 and the person is fully awake and
 alert during zo minute treatment ses-
 sions." Therefore, the term "side
 effect" was mentioned only to indi-
 cate that there were none in this
 study. Descriptions of nine studies
 (3%) altered the appearance of the
 text reporting financial incentives-
 three used bold, two used italics, one
 used capital letters, and one used an
 exclamation point. Of note, only z%
 of the diabetes recruitment sites and
 14% of the depression sites explicitly
 mentioned a source of funding.
 Sixty-seven percent (N = 115) of
 the diabetes studies and 77% (N =
 142) of the depression studies report-
 ed involving an intervention and/or
 procedure that appeared to be more
 than minimal risk (e.g., administer-
 ing a drug or use of a device). As
 shown in Table z (http://
 www.thehastingscenter.org/pdf/irb_
 zoo7_nov_dec_klitzman_tables.pdf),
 of these, most (75% diabetes and
 73% depression) reported an incen-
 tive. In addition, most were clinical
 trials conducted by a for-profit enti-
 ty. Most also did not list number of
 visits or length of study, and only a
 few mentioned a procedure, other
 than administration of a medication
 or device, that appeared to be more-
 than-minimal risk.
 Overall, as seen in Table 1 (http://
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 zoo7_nov_dec_klitzman_tables.pdf),
 diabetes and depression studies did
 not differ significantly in the rates at
 which they listed any incentives, but
 other differences did emerge.
 Diabetes studies were less likely than
 depression studies to list nonmone-
 tary incentives (i.e., free medications
 or treatment) or to involve any pro-
 cedure (i.e., intervention or assess-
 ment) that appeared to present
 more-than-minimal-risk. They were
 also more likely to list the number of
 visits required and to be conducted
 by a for-profit entity. There was a
 trend for diabetes studies to list
 financial incentives more frequently
 than depression studies. Given these
 differences, we then explored within
 each disease category whether those
 studies that listed financial incentives
 differed from other studies (Table 1,
 http://www.thehastingscenter.org/pdf/
 irb_zoo7_novdecklitzman_tables.p
 df). For diabetes, those that listed
 financial incentives were more likely
 to list nonmonetary incentives as
 well, to give study length, and to
 involve any procedure that appeared
 to be more-than-minimal-risk. For
 depression, those that mentioned
 financial incentives were more likely
 to involve any procedure that appar-
 ently involved more-than-minimal
 risk and to list the required number
 of visits. For both diseases, presence
 of financial incentives did not differ
 between for-profit and not-for-profit
 studies, as indicated through either
 source of funding listed or institu-
 tional affiliation of contact.
 For both diabetes and depression,
 those studies that appeared to
 involve a more-than-minimal-risk
 intervention were more likely to be
 clinical trials, to be funded or con-
 ducted by a for-profit entity, and to
 list a nonmonetary incentive.
 Among studies that appeared to
 pose more-than-minimal risk, dia-
 betes studies were more likely than
 depression studies to be clinical trials
 and to list number of visits. These
 diabetes studies also were less likely
 to be funded or conducted by a for-
 profit entity or to list a nonmonetary
 incentive and, as a trend, to list
 financial incentives and a specific
 amount.
 We then examined the number of
 studies that mentioned an incentive
 of any kind but did not list either
 length of study or number of visits
 required for participation, and thus
 appeared to be providing an unbal-
 anced view of the study. As indicated
 in Table 3 (http://www.thehastings-
 center.org/pdf/irb_zoo7_nov_dec_
 klitzman_tables.pdf), we found that
 38% of all studies (34% diabetes
 and 42% depression) fit this descrip-
 tion. Diabetes and depression stud-
 ies-both separately and when com-
 bined-that appeared to be provid-
 ing such an unbalanced view of the
 study were more likely to be con-
 ducted by a for-profit entity (p <
 o.ooo).
 Discussion
 Our examination is the first we
 know of to sample systematical-
 ly online sites that recruit study par-
 ticipants and to do so by specific dis-
 ease. We found that 38% (N = 136)
 of the sites (34% and 42% for dia-
 betes and depression, respectively)
 did not appear to provide balanced
 descriptions of the studies. Nearly
 three-quarters of the sites appeared
 to provide more than merely "direc-
 tory listing of descriptive informa-
 tion," in that they provided some
 description of incentives; yet roughly
 half of these failed to mention risks
 or what participation in the study
 involved (i.e., length of study or
 number of visits). No sites used the
 term "risk(s)," and only one site
 used the term "side effect(s)" (and
 then only to note their absence).
 Overall, most did not list length of
 study or number of visits. Even
 among studies that involved more-
 than-minimal-risk procedures, most
 did not mention what the study
 required, yet 75% of the diabetes
 studies and 73% of the depression
 studies mentioned an incentive, with
 50% of the diabetes studies and
 40% of the depression studies refer-
 ring specifically to a financial incen-
 tive.
 One might argue that the Web
 sites we examined provide only ini-
 tial presentations of study descrip-
 tions and thus comply with the FDA
 and OHRP guidance, yet neither
 guidance includes incentives in its list
of basic descriptive information that
 can be part of mere "directory list-
 ings."20 The OHRP guidance also
 notes that any additional informa-
 tion s ould be "presented in a bal-
 anced and fair manner." Our data
 show that many online recruiting
 sites include some-but not full-
 des riptions of what will be involved
 for individuals who decide to enroll
 in he studies listed. Thus, the infor-
mation provided appears inconsis-
tent with federal guidance and
 weighted toward encouraging
 research participation.
 One could also argue that persons
 who obtain information from clinical
 trial Web sites will receive additional
 data about potential research risks
 and requirements of participation
 during the informed consent process
 if they inquire further about partici-
 pating in the studies listed. Yet
 although Web-based presentations
 about clinical trials are not formal
 informed consent documents, they
 represent initial contact with poten-
 tial participants that may influence
 subsequent views and potential inter-
 est in enrolling. The federal guidance
 reflects this concern. Moreover,
 unlike advertisements in print media
 such as newspapers, Web sites have
 essentially unlimited space to present
 information regarding a study. In
 theory, Web sites used for recruit-
 ment could present a balanced pic-
 ture of the tasks required and the
 potential risks involved, particularly
 when financial incentives are provid-
 ed.
 Of concern as well is the fact that
 recruitment Web sites that appeared
 out of balance were more likely to be
 sponsored by for-profit entities, and
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 that the majority of studies examined
 did not explicitly describe the
 research sponsor. Financial conflicts
 of interest are of increasing concern
 in biomedical research.2" Prior stud-
 ies have shown that most clinical tri-
 als are industry-funded, and that, of
 these, those that report that an
 author who published the study
 results had a conflict of interest were
 nearly five times more likely to
 report a positive result." Hence, the
 source of funding for a study may
 well be important for potential study
 participants to be aware of, as it may
 affect the degree to which they trust
 investigators.
 How might the problems we dis-
 covered be ameliorated? Federal
 guidance says that "IRBs should pay
 particular attention to risk and
 potential benefit information to
 ensure it is presented in a balanced
 and fair manner." Insofar as many of
 the Web sites we studied went
 beyond basic descriptive informa-
 tion, they should have been subject
 to IRB review, but our data do not
 speak to the frequency with which
 review occurred. If IRBs were rou-
 tinely involved, these results suggest
 that these IRBs have given insuffi-
 cient attention to the content of
 study Web sites. In reviewing this
 material, IRBs should recognize that
 the inherent attributes of a Web site
 permit more information to be pro-
 vided than is feasible in newspaper
 or radio advertisements. We are not
 suggesting that complete informed
 consent documents should be posted
 every time a clinical trial is adver-
 tised. Flooding potential subjects
 with information at an early stage of
 recruitment without having research
 staff available to respond to ques-
 tions is likely to prove confusing.
 Rather, the goal, as reflected in feder-
 al guidance, should be balance in
 providing a realistic view of partici-
 pation. To the extent that benefits or
 incentives are mentioned, the
 requirements associated with partici-
 pation and potential risks should be
 noted as well. No template will fit
 every study, but the goal in each case
 is similar: to provide prospective
 subjects with a more complete pic-
 ture of a study's sponsorship, bene-
 fits, risks, procedures, and enroll-
 ment incentives.
 We note that modifying the feder-
 al guidance may help to accomplish
 this goal. By allowing "directory list-
 ings" to bypass IRB review, the cur-
 rent guidance encourages sponsors
 and investigators to limit the amount
 of information provided in Web-
 based contacts with potential sub-
 jects. The fact that information
 about incentives is nonetheless often
 included-though it does not meet
 the definition of "basic descriptive
 information"-suggests how difficult
 it may be to persuade researchers, in
 interactions with potential subjects,
 to refrain from "selling" participa-
 tion in their studies. Were the OHRP
 and the FDA to recognize this reality,
 they might well modify their guid-
 ance to suggest that all outreach
 efforts, including directory listings,
 be reviewed prospectively by IRBs.
 The costs of such a process in delay
 and IRB workload should not be
 ignored, but in our view, the benefits
 to potential subjects of a more accu-
 rate understanding of what is
 entailed in joining a study are vital to
 consider.
 This study has certain limitations.
 We examined only a portion of the
 Web sites that provide information
 about clinical trials, and we explored
 only two disease areas of clinical
 research. Although we have no rea-
 son to believe that these areas do not
 represent clinical research in general,
 further exploration of that question
 is warranted. Moreover, Internet
 practices are fluid. These results rep-
 resent only a snapshot in time of
 recruitment Web sites. Ongoing
 monitoring and follow-up of this sit-
 uation over time is clearly needed.
 Comparable studies of other venues
 in which clinical research studies are
 advertised would be helpful as well.
 Nonetheless, these data suggest that
 in their initial contact with studies,
 research participants recruited via
 the Internet may not receive bal-
 anced presentations of the implica-
 tions of participation, and that at
 least the spirit, if not the letter, of
 federal guidance is often not fol-
 lowed. More IRB oversight should
 not be unduly burdensome and
 could help ensure that potential sub-
 jects receive sufficient and balanced
 information from clinical trial Web
 sites.
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